Arbor Pharmaceuticals and its partners have multiple projects under various stages of development. We develop both new chemical entities as well as already approved molecules for new indications or in improved dosage forms. Our research scientists have extensive experience in clinical development and work collaboratively with the FDA to obtain market approval. The company has already filed four New Drug Applications (NDAs), all of which have been approved and also has several additional products in late-stage development. The projects currently in clinical development are shown below.